Residual effects of intra-articular betamethasone and triamcinolone acetonide in an equine acute synovitis model.
Authors: Partridge Emma, Adam Emma, Wood Courtney, Parker Jordan, Johnson Mackenzie, Horohov David, Page Allen
Journal: Equine veterinary journal
Summary
# Editorial Summary Intra-articular corticosteroid injections remain a cornerstone of equine joint management, yet questions persist about their residual anti-inflammatory effects beyond the intended treatment window. Partridge and colleagues administered either 9 mg betamethasone or triamcinolone acetonide to the radiocarpal joints of five horses, then challenged the joints with lipopolysaccharide two weeks later to simulate acute synovitis, measuring inflammatory markers (IL-6, PTGS1), serum amyloid A, cortisol, and lameness across multiple timepoints in a crossover design. Triamcinolone demonstrated substantially greater residual effects than betamethasone, significantly suppressing IL-6, cyclooxygenase-1 expression, lameness, and SAA concentrations at the time of LPS challenge, whilst betamethasone only affected IL-6; both agents produced prolonged cortisol suppression even weeks after injection. The findings suggest that current regulatory guidance on intra-articular corticosteroid intervals may underestimate residual anti-inflammatory activity, particularly for triamcinolone, and highlight an important safety consideration: the significant systemic cortisol suppression observed warrants careful risk–benefit analysis, especially in performance horses where immunosuppression and HPA axis dysregulation carry potential consequences. Though the acute LPS model produces more severe inflammation than typical degenerative joint disease, the results indicate that practitioners should account for differential steroid persistence when planning competition schedules and consider the systemic implications alongside local joint benefits.
Read the full abstract on PubMed
Practical Takeaways
- •Triamcinolone acetonide has more prolonged residual anti-inflammatory effects than betamethasone when injected intra-articularly, which should be considered when managing competition horses and regulatory compliance.
- •Both intra-articular corticosteroids suppress systemic cortisol production significantly; practitioners should monitor for potential systemic effects and weigh benefits against risks of HPA axis suppression.
- •Residual anti-inflammatory effects from intra-articular corticosteroid injections may persist beyond typical withdrawal periods, particularly in naturally occurring joint disease conditions.
Key Findings
- •Triamcinolone acetonide produced significant residual anti-inflammatory effects on IL-6, PTGS1, lameness, SAA and cortisol after LPS-induced acute synovitis, whereas betamethasone only affected IL-6 expression.
- •Both corticosteroids caused significant and prolonged cortisol suppression even when administered as corticosteroid-only treatments without LPS challenge.
- •The acute synovitis model produced significant inflammation but may not reflect the low-grade inflammation seen in typical clinical joint disease, potentially underestimating residual effects.
- •Current regulatory guidelines regarding intra-articular corticosteroid administration may be insufficient to account for residual anti-inflammatory effects in naturally occurring joint disease.